Menu
Recruiting NCT07414693

Effect of Vitamin C on Length of Hospital Stay in Children With Severe Pneumonia

Phase IV Interventional Pneumonia Childhood Vitamin C Hospital Stay Time

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Antibiotics administration, Vitamin C.
Who it may be relevant to
Registry conditions: Pneumonia Childhood, Vitamin C, Hospital Stay Time. Basic parameters: 2 months — 59 months · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Pakistan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Efficacy of Vitamin C as an Adjunct to Standard Treatment in Severe Pneumonia in Children Under Five Years of Age: A Clinical Comparison

Overview

Severe pneumonia is a common and serious illness in young children and often requires hospital admission. This clinical trial aims to find out whether adding vitamin C to standard treatment can reduce the length of hospital stay in children under five years of age admitted with severe pneumonia. The main question this study seeks to answer is: Does giving vitamin C along with routine treatment help children with severe pneumonia recover faster and go home earlier compared to standard treatment alone? In this study, 90 children aged 2 to 59 months who are admitted to the Children's Hospital Multan with severe pneumonia will take part. Severe pneumonia is defined by fast breathing, fever, cough, and one or more danger signs such as difficulty feeding, repeated vomiting, seizures, bluish discoloration of lips, or noisy breathing. Children with chronic lung disease or weakened immunity will not be included. After parental consent, children will be randomly divided into two groups. One group will receive standard treatment only, which includes oxygen therapy and intravenous antibiotics according to hospital protocol. The second group will receive the same standard treatment plus a daily dose of vitamin C. Neither group will receive any experimental or unapproved therapy. Researchers will closely monitor each child's recovery, including improvement in breathing rate, temperature, oxygen levels, and overall clinical condition. The child will be discharged when the treating physician determines that recovery criteria are met. The number of days spent in the hospital from the start of treatment until discharge will be recorded. By comparing the average hospital stay between the two groups, this study aims to determine whether vitamin C is a useful and safe add-on treatment for severe pneumonia in young children. The findings may help improve care and reduce hospital stay for children with severe pneumonia in the future.

Interventions

  • Drug Antibiotics administration
    Antibiotics Plus supportive care including oxygen inhalation, intravenous rehydration, and antipyretics
  • Drug Vitamin C
    Standard care (oxygen inhalation, intravenous rehydration, and antipyretics) plus Vitamin C: 200-mg (2 cc = 4 dropper, should be mixed in milk or water) once a day

Primary outcome measures

  • Hospital Stay [Time frame: From randomization to hospital discharge, assessed at discharge (up to 30 days).]

Eligibility criteria

Inclusion criteria

  • presenting with severe pneumonia
  • ≤ 48-hours duration

Exclusion criteria

  • Congenital heart disease
  • Children with chronic respiratory illnesses i.e. Asthma, post tuberculosis bronchiectasis and cystic fibrosis
  • Immunosuppressed i.e. primary immune deficiency, malignancy, on steroid therapy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Pakistan · 1 center
  • Children Hospital and Institute of Child Health — Multan Khurd

Identifiers

NCT: NCT07414693 · U1111-1334-9511

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗